Weight Watchers Adds Eli Lilly’s Oral GLP-1 Foundayo to Med+ Portfolio
Event summary
- Weight Watchers (WW) now offers Eli Lilly’s newly FDA-approved oral GLP-1 medication, Foundayo®, through its Med+ offering.
- Foundayo® is a once-daily, injection-free option for adults with obesity or weight-related medical problems.
- Self-pay pricing for Foundayo® starts at $149 per month for the lowest dose.
- WW’s Med+ members who engaged with the GLP-1 Success Program lost 29.1% more body weight on average over 12 months.
The big picture
Weight Watchers is expanding its Med+ portfolio with Eli Lilly’s oral GLP-1 medication, Foundayo®, reinforcing its position as a leader in science-backed weight management. This move aligns with the broader industry trend of integrating pharmaceutical solutions with behavioral support programs to address obesity. The addition of Foundayo® provides WW with a competitive edge in offering diverse treatment options, potentially attracting a broader member base and driving revenue growth.
What we're watching
- Market Differentiation
- How WW’s integration of Foundayo® will position it against competitors in the GLP-1 market.
- Adoption Rates
- The pace at which WW members adopt Foundayo® and its impact on WW’s revenue growth.
- Regulatory Compliance
- Whether WW can sustain its clinical support model amid evolving FDA guidelines for GLP-1 treatments.
Related topics